A recent Children’s Hospital Los Angeles study led by Principal Investigator Michael Goran, PhD, and Rachel Schenker, MD, a Fellow in the CHLA Liver Transplant Program, has found a novel combination of plasma-based biomarkers that could potentially predict liver fibrosis linked to metabolic dysfunction‐associated steatotic liver disease (MASLD)–the most common pediatric liver disease in the U.S.
